Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL)
- Autori: Novo, M.; Manlio Mirko Frascione, P.; Castellino, A.; Marcheselli, L.; Deianira Dattoli, S.; Vannucchi, M.; Rota-Scalabrini, D.; Tucci, A.; Gini, G.; Tarantini, G.; Mannina, D.; Arcari, A.; Liso, A.; Scarpa, E.; Marino Michele Spina, D.; Gorgone, A.; Di Renzo, N.; Mancuso, S.; Petrucci, L.; Tafuri, A.; Botto, B.; Bonello, F.; Santambrogio, E.; Vitolo, U.
- Anno di pubblicazione: 2025
- Tipologia: Articolo in rivista
- OA Link: http://hdl.handle.net/10447/687247
Abstract
Treatment options for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) patients ineligible for autologous stem cell transplant (ASCT) or chimeric antigen receptor (CAR)-T-cell therapy remain limited. The PI3K inhibitor copanlisib has shown activity as a single agent in DLBCL. This phase II, single-arm, multicentre trial evaluated copanlisib with rituximab and bendamustine (copa-BR) in ASCTand CAR-T-ineligible R/R DLBCL. Patients received six cycles of copa-BR, followed by up to 12 cycles of copanlisib maintenance. The primary end-point was 12-month progression-free survival (PFS). Thirty-seven patients (aged 68–87 years, R/R after 1–2 prior lines) were enrolled. The overall response rate was 24.3%, with complete responses in 13.5%. After a median follow-up of 20 months, the 12-month PFS and overall survival rates were 25.1% and 44.5% respectively. Grade ≥3 toxicities included neutropenia (56.8%), infections (27.0%, including 6 death due to COVID-19 infection with 25% fatality) and thrombocytopenia (16.2%). Due to limited efficacy, poor tolerability and emerging alternative treatments, the trial was terminated prematurely. Copa-BR showed limited activity and an unfavourable safety profile, discouraging further investigation of this combination in ASCT- and CAR-Tineligible R/R DLBCL.